SEP 20, 2019 6:43 PM PDT

Leukemia Drug Effective for Treating Childhood Brain Cancer

WRITTEN BY: Nouran Amin

Scientists at the University of California-San Diego have found that a chronic myeloid leukemia drug was found to treat medulloblastoma in mouse models more effectively than existing therapeutics. Findings of the study were published in PLOS One and demonstrates how the use of the single FDA-approved drug ‘nilotinib’ targets cancer cells that have been abnormally activated through a specific cell communication system known as the Hedgehog pathway.

Learn more about the Hedgehog Pathway:

"We discovered a previously unknown activity of nilotinib that may be leveraged to treat a large fraction of cases of medulloblastoma, a type of childhood brain cancer," said senior author Ruben Abagyan, PhD, professor in the Skaggs School of Pharmacy. "While more research is needed, this pharmaceutical could potentially be used for several cancer types with an overactive cell-signaling pathway."

Many types of cancer have an impaired hedgehog pathway such as basal cell carcinoma, myeloid leukemia, rhabdomyosarcoma, pancreatic adenocarcinoma, glioblastoma and one third of medulloblastoma cases. The Hedgehog pathway is a critical cellular system that regulates embryonic development and adult tissue regeneration. When impaired, the pathway allows the cancer cells to overproduce a cell-surface receptor known as smoothened—this results in plenty of malignant cancers.

In the study, Nilotinib was found to inhibit the activity of smoothened and several other protein kinases implicated in tumor growth. This was demonstrated in mice bearing human medulloblastoma tumors which after the Nilotinib-treatment tumor growth was decreased with no apparent drug resistance.

"Only a fraction of patients with this subtype of medulloblastoma respond well to current therapies that only target Smoothened," said Abagyan. "Knowing that dysregulation of the Hedgehog pathway is important to the maintenance of cancer stem cells, and that it plays a critical role in several cancers, we wanted to find a single drug that inhibits this pathway in addition to several other essential anti-cancer activities."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 08, 2020
Drug Discovery & Development
MAY 08, 2020
Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People
While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidenc ...
MAY 18, 2020
Cancer
MAY 18, 2020
How do Ohnologs affect Cancer?
Genetics can be complicated to say the least. Sometimes it can be as simple as a single mutation in one gene that causes ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
COVID-19 Vaccine On Track for Late 2020
Moderna, a biotechnology company based in Massachusetts, has released information on its vaccine against COVID-19 from i ...
MAY 28, 2020
Cancer
MAY 28, 2020
The Oncogenic Hazard of a Potential Alzheimer's Treatment
Breast cancer remains one of the most common cancers around the world. Triple-Negative Breast Cancer (TNBC) is a sub-typ ...
JUN 09, 2020
Drug Discovery & Development
JUN 09, 2020
Arthritis Drug May Reduce COVID-19 Deaths by 45%
Researchers from the University of Michigan have found that tocilizumab, an immunosuppressive drug used to treat arthrit ...
JUN 23, 2020
Drug Discovery & Development
JUN 23, 2020
Psychedelic DMT to Enter Clinical Trials
Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinic ...
Loading Comments...